M&A - Nuo Therapeutics, Inc.

Form Type: 10-K

Filing Date: 2025-04-01

Corporate Action: Merger

Type: Update

Accession Number: 000143774925010379

Filing Summary: Nuo Therapeutics, Inc., previously known as Cytomedix, underwent significant structural changes including a merger and an eventual bankruptcy filing leading to its current operations. The company specializes in regenerative therapies, particularly products for chronic wound care. The main product is Aurix, a platelet-rich plasma technology launched for managing chronic wounds. Financial performance indicates growth, with reported revenues of approximately $1,365,000 for the year 2024, and expectations for continued growth due to a newly established Distribution Agreement with Smith+Nephew that stipulates purchase commitments and exclusive distribution rights. The company has faced numerous challenges including limited revenue, reliance on reimbursements, and the need for effective marketing strategies to penetrate the competitive wound care market.

Document Link: View Document